Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time?
- 209 Downloads
We would like to comment on the manuscript written by Esserman and colleagues  regarding the application of a decision analytic framework for adoption of clinical trial results. It is true that due to the prevalence of breast cancer, any management decision concerning its treatment may have significant implications concerning medical resources use and costs. However, this also holds true for any mistake or hasty decision that might carry a heavy price on public health in the long term.
If the purpose of the model presented in the article aimed to describe an analytic framework, then for the purpose of proof of concept, the statistical analysis should be applied first on treatments for which long-term follow-up is available, in order to prove and validate that the model can predict the same results as in the reality of daily practice. The use of the currently available TARGIT-A trial data to evaluate this model is inappropriate since follow-up in the TARGIT-A trial is immature [2, 3]...
KeywordsHigh Local Recurrence Rate Adjuvant Hormonal Treatment Hasty Decision Staff Safety Decision Analytic Framework
Conflict of interest
- 2.Vaidya JS, Wenz F, Bulsara M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. doi: 10.1016/S0140-6736(13)61950-9 CrossRefPubMedGoogle Scholar
- 9.Kaidar-Person O, Yarnold J, Offersen BV, Poortmans P (2014) Is current evidence about intraoperative partial breast irradiation sufficient for broad implementation in clinical practice? Eur J Surg Oncol 27. doi: 10.1016/j.ejso.2014.03.014